
NuScale Power's Small Modular Reactor (SMR) Achieves Standard Design Approval from U.S. Nuclear Regulatory Commission for 77 MWe
CORVALLIS, Ore.--(BUSINESS WIRE)--NuScale Power Corporation (NYSE: SMR), the industry-leading provider of proprietary and innovative advanced small modular reactor nuclear technology, today announced that it has received design approval from the U.S. Nuclear Regulatory Commission (NRC) for its uprated 250 MWt (77 MWe) NuScale Power Modules™.
The U.S. NRC's uprate approval of the NuScale SMR technology now strengthens ENTRA1 Energy to produce and deliver energy as the most near-term American SMR power solution via ENTRA1 Energy Plants™ with NuScale SMR technology inside. ENTRA1 Energy is NuScale's partner and independent power plant development platform, which holds the global exclusive rights to the commercialization, distribution, and deployment of NuScale's SMRs.
The uprate approval by the U.S. regulatory authority increases the power output per module from NuScale's previously-approved 50 MWe design, enabling ENTRA1 Energy Plants to provide a wider range of off-takers and consumers with reliable, carbon-free energy. NuScale remains the only SMR technology company with design approval from the NRC, and the company remains on track for deployment by 2030.
'We are thrilled that the NRC has approved our second SDA application, this time for our 77 MWe design. This marks a historic moment not only for NuScale, but the entire industry, as NuScale and ENTRA1 move closer to meeting the demands of clean energy users,' said John Hopkins, NuScale President and Chief Executive Officer. 'For more than a decade, our team has proudly worked alongside the NRC to achieve the successful approval of our designs. The NRC is domestically and internationally recognized and respected for its rigorous safety standards, and this approval is a crucial step toward meeting our goal of providing clean, reliable, and, most importantly, safe energy to off-takers and consumers.'
NuScale's first Design Certification Application (DCA) for its 160 MWt (50 MWe) SMR design was accepted by the NRC in March 2017. Subsequently, the NRC affirmed its approval of NuScale's 50 MWe SMR design, marking the first design to receive its approval.
NuScale's uprated design features the same fundamental safety case and passive safety features previously approved by the NRC with a power uprate and select design changes to support growing capacity needs. Originally slated for approval later this summer, today's announcement marks the early completion of the NRC review process.
'NuScale is proud to have worked with the NRC and to have met its stringent regulatory application process as we continue to lead the way in the SMR industry with our second design approval,' said Carrie Fosaaen, Vice President of Regulatory Affairs and Services. 'With today's announcement, NuScale continues to advance with ENTRA1 Energy in the commercialization of our SMR technology inside ENTRA1 Energy Plants while remaining steadfast in our mission to improve the quality of life for people around the world through safe, clean energy.'
About NuScale Power
Founded in 2007, NuScale Power Corporation (NYSE: SMR) is the industry-leading provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. The Company's groundbreaking SMR technology is powered by the NuScale Power Module™, a small, safe, pressurized water reactor that can each generate 77 megawatts of electricity (MWe) or 250 megawatts thermal (gross), and can be scaled to meet customer needs through an array of flexible configurations up to 924 MWe (12 modules) of output.
As the first and only SMR to have its designs certified by the U.S. Nuclear Regulatory Commission, NuScale is well-positioned to serve diverse customers across the world by supplying nuclear energy for electrical generation, data centers, district heating, desalination, commercial-scale hydrogen production, and other process heat applications.
To learn more, visit NuScale Power's website or follow us on LinkedIn, Facebook, Instagram, X, and YouTube.
About ENTRA1 Energy
ENTRA1 Energy is an American independent global energy production platform dedicated to increasing energy security by providing safe, reliable, cost-effective, and environmentally responsible electric power. ENTRA1 Energy is NuScale's exclusive global strategic partner and holds the global exclusive rights to the commercialization, distribution, and deployment of all NuScale's products and services. ENTRA1 is the one-stop-shop and single hub for the financing, investment, development, execution, and/or management of ENTRA1 Energy Plants™ with NuScale SMRs-inside.
To learn more, visit ENTRA1 ENERGY's website or follow us on LinkedIn and X.
Forward Looking Statements
This release contains forward-looking statements (including without limitation statements containing terms such as "will," "believes," "expects," 'anticipates,' "plans" or other similar expressions). These forward-looking statements include statements relating to our SMR design's ability to support a wider range of off-takers, consumers and customers with energy, progress with respect to meeting the demands of clean energy users, our leadership in the SMR industry, our ability to deploy and the timeline for deployment, advancement of the commercialization of SMR technology, strategic and operational plans and expectations, the growth in demand for clean energy, capital deployment, future growth, new awards, backlog, earnings and the outlook for the Company's business.
Actual results may differ materially as a result of a number of factors, including, among other things, the Company's liquidity and ability to raise capital; the Company's failure to receive new contract awards; cost overruns, project delays or other problems arising from project execution activities, including the failure to meet cost and schedule estimates; our expectations regarding obtaining regulatory approvals, and the timing thereof, to deploy our SMRs in the United States and abroad; forecasts regarding end-user adoption rates and demand for our products in the markets that are new and rapidly evolving; limitations on the effectiveness of our controls and procedures and our remediation plans related thereto; intense competition in the industries in which we operate; failure of our partners to perform their obligations; cyber-security breaches; foreign economic and political uncertainties; client cancellations of, or scope adjustments to, existing contracts; failure to maintain safe worksites and international security risks; risks or uncertainties associated with events outside of our control, including weather conditions, pandemics (including COVID-19), public health crises, political crises or other catastrophic events; macroeconomic conditions; the use of estimates and assumptions in preparing our financial statements; client delays or defaults in making payments; the failure of our suppliers, subcontractors and other third parties to adequately perform services under our contracts; uncertainties, restrictions and regulations impacting our government contracts; the inability to hire and retain qualified personnel; the potential impact of certain tax matters; possible information technology interruptions; the Company's ability to secure appropriate insurance; liabilities associated with the performance of nuclear services; foreign currency risks; the loss of one or a few clients that account for a significant portion of the Company's revenues; damage to our reputation; failure to adequately protect intellectual property rights; asset impairments; climate change and related environmental issues; increasing scrutiny with respect to sustainability practices; the availability of credit and restrictions imposed by credit facilities for our clients, suppliers, subcontractors or other partners; failure to obtain favorable results in existing or future litigation and regulatory proceedings, dispute resolution proceedings or claims, including claims for additional costs; failure by us or our employees, agents or partners to comply with laws; new or changing legal requirements, including those relating to environmental, health and safety matters; failure to successfully implement our strategic and operational initiatives and restrictions on possible transactions imposed by our charter documents and Delaware law. Caution must be exercised in relying on these and other forward-looking statements. Due to known and unknown risks, the Company's results may differ materially from its expectations and projections.
Additional information concerning these and other factors can be found in the Company's public periodic filings with the Securities and Exchange Commission (the 'SEC'), including the general economic conditions and other risks, uncertainties and factors set forth in the section entitled 'Cautionary Note Regarding Forward-Looking Statements' and 'Summary of Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in subsequent filings with the SEC. The referenced SEC filings are available either publicly or upon request from NuScale's Investor Relations Department at ir@nuscalepower.com. The Company disclaims any intent or obligation other than as required by law to update the forward-looking statements.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
33 minutes ago
- Yahoo
Analysts assess the potential impact of Trump's surprise 50% steel tariffs
-- U.S. President Donald Trump unexpectedly announced on Friday that steel and aluminum tariffs will double to 50%. The move, set to come into effect on June 4, was unveiled during a campaign rally in Pennsylvania. It was later confirmed on TruthSocial and comes amid broader debates around U.S. industrial policy and foreign investment. Analysts are now evaluating the implications of this surprise decision, with most agreeing that the immediate domestic effects may be less severe than the broader geopolitical risks. JPMorgan's Tatsuya Maruyama said the direct impact on major Japanese steelmakers such as Nippon Steel Corp (TYO:5401), JFE Holdings, Inc. (TYO:5411), and Kobe Steel, Ltd. (TYO:5406) is expected to be limited, given that 'the U.S. accounts for about 4% of Japan's steel exports.' Maruyama pointed out in a Monday note that Nippon Steel and JFE export only about 1% of their total shipments to the U.S., while Kobe Steel exports about 3%. Still, he warned that 'rising global protectionism' is a growing concern, noting that a wave of anti-dumping measures and safeguards in regions like South Korea, the EU, and India could further strain global trade dynamics. 'If such countermeasures gain momentum, Japanese steel products may also be targeted and the export environment may worsen,' Maruyama continued. Meanwhile, analysts at BMO Capital Markets believe the sudden tariff hike could jolt domestic markets. 'The doubling of import tariffs, if maintained, is likely to create a panic in the market and trigger a restocking cycle that in our view has the potential to push prices >$1,000/st in the near-term,' the analysts said. However, they believe the spike would be temporary given macro uncertainty and seasonal demand trends. The broker upgraded Nucor (NYSE:NUE) to Outperform but downgraded Algoma Central (TSX:ALC), which it called 'a relative tariff loser.' The aluminum market may be more exposed, according to BMO. The U.S. covers only about 20% of its own aluminum consumption domestically, making it more vulnerable to supply disruptions. 'If tariffs do double, this is expected to put material upside pressure on the Midwest premium (MWP),' BMO wrote, estimating it could reach '$0.75/lb-plus' in theory, although higher aluminum cost will likely weigh on demand and thus offset some upside pressure. That said, the brokerage sees Century Aluminum (NASDAQ:CENX) as well positioned to benefit from a rise in the Midwest premium, while Alcoa (NYSE:AA) could see a negative impact of $1–2 per share, or 4–7%, due to its reliance on Canadian production. Still, BMO expects Alcoa may redirect some of its Canadian output to the EU market. Related articles Analysts assess the potential impact of Trump's surprise 50% steel tariffs Street Calls of the Week VIDEO: How to analyze a stock like a pro with the CEO of HF Foods
Yahoo
34 minutes ago
- Yahoo
1 Value Stock on Our Buy List and 2 to Approach with Caution
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues. Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored. Forward P/E Ratio: 14.5x Synonymous with "dad shoe", Skechers (NYSE:SKX) is a footwear company renowned for its comfortable, stylish, and affordable shoes for all ages. Why Is SKX Risky? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Estimated sales growth of 7.4% for the next 12 months implies demand will slow from its two-year trend Poor free cash flow margin of 4.4% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends Skechers is trading at $62.04 per share, or 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than SKX. Forward P/E Ratio: 9.9x Established in 1878, Mohawk Industries (NYSE:MHK) is a leading producer of floor-covering products for both residential and commercial applications. Why Are We Out on MHK? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth ROIC of 3.5% reflects management's challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned At $100.61 per share, Mohawk Industries trades at 9.9x forward P/E. Check out our free in-depth research report to learn more about why MHK doesn't pass our bar. Forward P/E Ratio: 3.7x Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Are We Bullish on SRPT? Annual revenue growth of 51.3% over the last two years was superb and indicates its market share increased during this cycle Earnings per share grew by 38.8% annually over the last five years, massively outpacing its peers Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business Sarepta Therapeutics's stock price of $37.50 implies a valuation ratio of 3.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium, 02 June 2025 – Biocartis NV ('Biocartis'), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation (EU) 2017/746 (IVDR), making it the first Idylla™ Test to be certified as a Class C Companion Diagnostic (CDx) IVD Medical Device under the IVDR framework. The IVDR-certified Idylla™ EGFR Mutation Test is designed to serve as a CDx for the detection of EGFR exon 19 deletions and the L858R mutation, which are key biomarkers that guide targeted therapies for patients with non-small cell lung cancer (NSCLC). The IVDR certification confirms the Test's compliance with Europe's rigorous new regulatory standards, ensuring enhanced patient safety, improved information transparency, and robust data traceability. Designed for use on the Idylla™ Platform, the Test qualitatively detects 44 mutations across exons 18, 19, 20, and 21 of the EGFR gene – all within a single cartridge. Among these, exon 19 deletions and L858R mutations are validated as CDx targets, and the remaining mutations have been analytically validated. Utilizing formalin-fixed, paraffin-embedded (FFPE) tissue samples, the Test is fully automated from sample to result, delivering fast results in under 3 hours – streamlining laboratory workflows and empowering oncologists with timely treatment decisions for their patients. With 99.2% sensitivity (PPA) and 99.0% specificity (NPA) for the CDx targets, the Idylla™ EGFR Mutation Test ensures accurate detection of key EGFR mutations, providing healthcare professionals with actionable results to guide treatment decisions in NSCLC. For more information about the Test, please visit the Biocartis website or contact the Biocartis team. While the IVDR-certified Idylla™ EGFR Mutation Test is now available to customers across Europe, with availability in other non-US markets expected to follow progressively – Biocartis is also developing the Idylla™ EGFR CDx Test in the US with AstraZeneca. Upon approval, the Test will be intended to help identify patients with NSCLC who may respond to treatment with Tagrisso® (Osimertinib), AstraZeneca's third-generation EGFR-TKI treatment. Roger Moody, Chief Executive Officer of Biocartis, commented: 'Achieving IVDR certification for our Idylla™ EGFR Mutation Test is a key milestone for Biocartis and reinforces our commitment to quality and regulatory excellence. This is the first Idylla™ Test to be certified under the new IVDR framework, and we are currently pursuing certification of additional Tests in our portfolio. The IVDR establishes more rigorous standards to improve patient safety and diagnostic accuracy, and we are proud to be at the forefront of this evolution in European diagnostics.' ----- END ----- More information: info@ Biocartis NV. Generaal De Wittelaan 11B, 2800 Mechelen, Belgium About Biocartis With its revolutionary and proprietary Idylla™ Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, easy, fast and suitable for any lab. The Idylla™ Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house molecular biomarker testing in only 3 hours, allowing fast and optimal treatment selection. Idylla™'s continuously expanding menu of molecular diagnostic tests and research assays addresses key unmet clinical needs. Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer. More information: Follow us on LinkedIn, Facebook and X (Twitter). Disclaimers Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries. Idylla™ EGFR Mutation Test (A0270/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR). Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis NV. © June 2025, Biocartis NV. All rights lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données